Diagnosis and treatment of cancer using anti-EREG antibody
Methods that entail detection of an epiregulin (EREG) protein for cancer diagnosis are disclosed. In colon cancer, lung adenocarcinoma, pancreatic cancer, stomach cancer, and kidney cancer, the gene and protein expressions of EREG were frequently found to be elevated. Antibodies that recognize an EREG protein are used for diagnosing or treating cancer in the present invention. Pharmaceutical compositions, cell proliferation inhibitors, and anticancer agents containing an EREG-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in EREG-expressing cells and methods of suppressing the proliferation of EREG-expressing cells by contacting the EREG-expressing cells with EREG-binding antibodies are also disclosed.
1. An anticancer agent comprising as an active ingredient a monoclonal antibody that binds to an EREG protein, wherein said antibody has cytotoxicity, neutralizing activity, or both, for the treatment of a cancer selected from the group consisting of colon cancer, lung cancer, and pancreatic cancer, and wherein said antibody is an antibody of any of (1) to (43) below:
(1) an antibody comprising an H chain having the amino acid sequence of SEQ ID NO: 2 as CDR1, the amino acid sequence of SEQ ID NO: 4 as CDR2, and the amino acid sequence of SEQ ID NO: 6 as CDR3, and an L chain having the amino acid sequence of SEQ ID NO:12 as CDR1, the amino acid sequence of SEQ ID NO:14 as CDR2, and the amino acid sequence of SEQ ID NO:16 as CDR3;
(2) an antibody comprising the H chain and the L chain of (1), wherein the H chain has the amino acid sequence of positions 117 to 452 in the amino acid sequence of SEQ ID NO: 8 as CH;
(3) an antibody comprising the H chain and the L chain of (1), wherein the H chain has the amino acid sequence of positions 117 to 446 in the amino acid sequence of SEQ ID NO: 10 as CH;
(4) an antibody comprising the H chain and the L chain of (1), wherein the L chain has the amino acid sequence of positions 107 to 213 in the amino acid sequence of SEQ ID NO: 18 as CL;
(5) an antibody comprising the H chain and the L chain of (1), wherein the L chain has the amino acid sequence of positions 107 to 213 in the amino acid sequence of SEQ ID NO: 20 as CL;
(6) an antibody comprising the H chain of (2) and the L chain of (4);
(7) an antibody comprising the H chain of (3) and the L chain of (5);
(8) an antibody comprising an H chain having the amino acid sequence of SEQ ID NO: 49 as CDR1, the amino acid sequence of SEQ ID NO: 51 as CDR2, and the amino acid sequence of SEQ ID NO: 53 as CDR3, and an L chain having the amino acid sequence of SEQ ID NO:55 as CDR1, the amino acid sequence of SEQ ID NO:57 as CDR2, and the amino acid sequence of SEQ ID NO:59 as CDR3;
(9) an antibody comprising the H chain and the L chain of (8), wherein the H chain has CH as derived from mouse IgG1;
(10) an antibody comprising the H chain and the L chain of (8), wherein the H chain has the amino acid sequence of positions 117 to 446 in the amino acid sequence of SEQ ID NO: 10 as CH;
(11) an antibody comprising the H chain and the L chain of (8), wherein the L chain has CL derived from the mouse κ chain;
(12) an antibody comprising the H chain and the L chain of (8), wherein the L chain has the amino acid sequence of positions 107 to 213 in the amino acid sequence of SEQ ID NO: 20 as CL;
(13) an antibody comprising the H chain of (9) and the L chain of (11);
(14) an antibody comprising the H chain of (10) and the L chain of (12);
(15) an antibody comprising an H chain having the amino acid sequence of SEQ ID NO: 61 as CDR1, the amino acid sequence of SEQ ID NO: 63 as CDR2, and the amino acid sequence of SEQ ID NO: 65 as CDR3, and an L chain having the amino acid sequence of SEQ ID NO:67 as CDR1, the amino acid sequence of SEQ ID NO:69 as CDR2, and the amino acid sequence of SEQ ID NO:71 as CDR3;
(16) an antibody comprising the H chain and the L chain of (15), wherein the H chain has CH derived from mouse IgG1;
(17) an antibody comprising the H chain and the L chain of (15), wherein the H chain has the amino acid sequence of positions 117 to 446 in the amino acid sequence of SEQ ID NO: 10 as CH;
(18) an antibody comprising the H chain and the L chain of (15), wherein the L chain has CL derived from the mouse κ chain;
(19) an antibody comprising the H chain and the L chain of (15), wherein the L chain has the amino acid sequence of positions 107 to 213 in the amino acid sequence of SEQ ID NO: 20 as CL;
(20) an antibody comprising the H chain of (16) and the L chain of (18);
(21) an antibody comprising the H chain of (17) and the L chain of (19);
(22) an antibody comprising an H chain having the amino acid sequence of SEQ ID NO: 73 as CDR1, the amino acid sequence of SEQ ID NO: 75 as CDR2, and the amino acid sequence of SEQ ID NO: 77 as CDR3, and an L chain having the amino acid sequence of SEQ ID NO:79 as CDR1, the amino acid sequence of SEQ ID NO:81 as CDR2, and the amino acid sequence of SEQ ID NO:83 as CDR3;
(23) an antibody comprising the H chain and the L chain of (22), wherein the H chain has CH derived from the mouse IgG1;
(24) an antibody comprising the H chain and the L chain of (22), wherein the H chain has the amino acid sequence of positions 117 to 446 in the amino acid sequence of SEQ ID NO: 10 as CH;
(25) an antibody comprising the H chain and the L chain of (22), wherein the L chain has CL derived from the mouse κ chain;
(26) an antibody comprising the H chain and the L chain of (22), wherein the L chain has the amino acid sequence of positions 107 to 213 in the amino acid sequence of SEQ ID NO: 20 as CL;
(27) an antibody comprising the H chain of (23) and the L chain of (25);
(28) an antibody comprising the H chain of (24) and the L chain of (26);
(29) an antibody comprising an H chain having the amino acid sequence of SEQ ID NO: 85 as CDR1, the amino acid sequence of SEQ ID NO: 87 as CDR2, and the amino acid sequence of SEQ ID NO: 89 as CDR3, and an L chain having the amino acid sequence of SEQ ID NO:91 as CDR1, the amino acid sequence of SEQ ID NO:93 as CDR2, and the amino acid sequence of SEQ ID NO:95 as CDR3;
(30) an antibody comprising the H chain and the L chain of (29), wherein the H chain has CH derived from the mouse IgG1;
(31) an antibody comprising the H chain and the L chain of (29), wherein the H chain has the amino acid sequence of positions 117 to 446 in the amino acid sequence of SEQ ID NO: 10 as CH;
(32) an antibody comprising the H chain and the L chain of (29), wherein the L chain has CL derived from the mouse κ chain;
(33) an antibody comprising the H chain and the L chain of (29), wherein the L chain has the amino acid sequence of positions 107 to 213 in the amino acid sequence of SEQ ID NO: 20 as CL;
(34) an antibody comprising the H chain of (30) and the L chain of (32);
(35) an antibody comprising the H chain of (31) and the L chain of (33);
(36) an antibody comprising an H chain having the amino acid sequence of SEQ ID NO: 97 as CDR1, the amino acid sequence of SEQ ID NO: 99 as CDR2, and the amino acid sequence of SEQ ID NO: 101 as CDR3, and an L chain having the amino acid sequence of SEQ ID NO:103 as CDR1, the amino acid sequence of SEQ ID NO:105 as CDR2, and the amino acid sequence of SEQ ID NO:107 as CDR3;
(37) an antibody comprising the H chain and the L chain of (36), wherein the H chain has CH derived from mouse IgG1;
(38) an antibody comprising the H chain and the L chain of (36), wherein the H chain has the amino acid sequence of positions 117 to 446 in the amino acid sequence of SEQ ID NO: 10 as CH;
(39) an antibody comprising the H chain and the L chain of (36), wherein the L chain has CL derived from the mouse κ chain;
(40) an antibody comprising the H chain and the L chain of (36), wherein the L chain has the amino acid sequence of positions 107 to 213 in the amino acid sequence of SEQ ID NO: 20 as CL;
(41) an antibody comprising the H chain of (37) and the L chain of (39);
(42) an antibody comprising the H chain of (38) and the L chain of (40); and
(43) an antibody that binds to the same EREG protein epitope as the antibody of any of (1) to (42).
2. The anticancer agent of claim 1 , wherein the cancer is a primary cancer.
3. The anticancer agent of claim 1 , wherein the cancer is a metastatic cancer.
4. The anticancer agent of claim 1 , wherein the cancer is colon cancer or lung cancer.